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Over the last twenty years, revolutionary advances in biomedicine including gene therapy, stem cell research, proteomics, genomics
and nanotechnology have highlighted the progressive need to restructure traditional approaches to basic and clinical research in
order to facilitate the rapid, eﬃcient integration and translation of these new technologies into novel eﬀective therapeutics. Over
the past ten years, funding bodies in the USA and UK such as the National Institutes of Health (NIH) and the Medical Research
Council (MRC) have been driving translational research by defining and tackling the hurdles but more still remains to be achieved.
This article discusses the ongoing challenges translational researchers face and outlines recent initiatives to tackle these including
the new changes to translational funding schemes proposed by the NIH and the MRC and the launch of the “European Advanced
Translational Research InfraStructure inMedicine” (EATRIS). It is anticipated that initiatives such as these will not only strengthen
translational biomedical research programmes already initiated but should lead to rapid benefits to patients and society.
1. Introduction
Translational research (TR) is a relatively new area of inves-
tigation that ideally involves the integrated application of
innovative technologies that encompass multiple disciplines
including physiology, pathophysiology, natural history of
disease, genetics, and proof-of-concept studies of drugs and
devices [1].
TR describes a continuum of research in which basic
science discoveries are utilized to prevent or treat human
disease. It is an iterative process wherein scientific discoveries
are integrated into clinical applications and, conversely,
clinical observations are used to generate research foci for
basic science: the “bench to bedside and back to bench”
approach.
Initially, 2 phases in TR were described:
T1. basic science discoveries used to develop new treat-
ments for disease (“bench to bedside”),
T2. research aimed at improving utilization of proven
therapies in clinical practice and community settings (“bed-
side to community”).
More recently, this has been redefined to include 3 phases
in TR, with the second phase being subdivided. Thus, in this
new model T1 describes basic science to clinical science, T2
clinical science to clinical practice, and T3 is used to denote
the translation of clinical practice to more widespread health
improvements [2].
Whilst the importance and benefits of TR are now
clear to most, significant challenges faced by investigators
have also been recognised. This article focuses on some of
those barriers and discusses whether initiatives over the past
decade to drive TR forward as broken them down.
2. Barriers to Translational Research
The essential role of TR in ensuring rapid progression of
basic scientific knowledge to patient benefit has been empha-
sised for more than 3 decades [3]. During this period, the
barriers to TR have also been identified. The main issues that
have been repeatedly debated include cultural diﬀerences
between basic scientists and clinicians, lack of resources in
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terms of workforce and infrastructure, and the complex
regulatory environment [4]. Cultural diﬀerences between the
two groups of investigators largely stem from the lack of
communication, diﬀerences in education and training, and
diﬀerent goals and reward mechanisms. Regulatory issues
are intimidating to both basic scientists and clinicians and
encompass ethics involved in human research, tissue bank-
ing and material transfer regulations, intellectual property
rights, toxicology and manufacturing regulations, Food and
Drug Administration (FDA) and Medicines and Healthcare
Regulatory Agency (MHRA) approvals, study sponsorship
and insurance, as well as trial and data monitoring. These
are becoming even more complex with expanding work in
the fields of cell and gene therapies and tissue engineering.
Resource problems include lack of trained interdisciplinary
staﬀ to support investigations throughout the TR cycle,
protected time for research particularly for clinicians, as
well as access to shared resources. Together, these issues
contribute to various checkpoints between the phases of TR
including the “valley of death” that exists between preclinical
research and clinical trials [5].
3. Streamlining Regulatory Issues
In addition to cultural diﬀerences, eﬀorts have been made to
streamline health research approvals and reduce regulatory
burdens. The NIHR developed the Integrated Research
Application System (IRAS) in 2008, an integrated online
system which captures information required for approval
application from several review bodies including the NHS
R&D oﬃces, research ethics committees, MHRA, Adminis-
tration of Radioactive Substances Advisory Committee, Gene
Therapy Advisory Committee, and the National Information
Governance Board. The Research Passport system was also
set up to streamline the issuing of honorary research
contracts for researchers not employed by the NHS. In
December 2011, the NHS launched the Health Research
Authority which will play a key role in research governance
and further streamline the approval process [6]. In the USA,
the National Center for Advancing Translational Sciences
(NCATS; http://www.ncats.nih.gov/) was established this
year (2012) with its mission to “catalyze the generation of
innovative methods and technologies that will enhance the
development, testing, and implementation of diagnostics
and therapeutics across a wide range of human diseases and
conditions.” This would include dealing with bottlenecks
such as regulatory issues in the TR process to make it “more
eﬃcient, less expensive and less risky” [7].
4. Training and Mentoring
Whilst regulatory issues are a major factor determining the
success of translational projects, it is also imperative that
we train and develop a pipeline of clinician-scientists and
applied scientists who are comfortable in dealing with the
continuing challenges of TR. During their training, clinician-
scientists would benefit from experience in laboratory
research whilst basic scientists should have exposure to the
clinical environment under the guidance of experienced clin-
icians. Both groups should also receive training in research
methodology including clinical trial design and conduct,
and medical statistics. Multidisciplinary academic medical
centres are well placed to oﬀer such training programmes
and indeed, the USA Clinical and Translational Sciences
Awards (CTSA) scheme has as its central strategy five goals
within which training and career development are firmly
embedded [8].
Goal 1. Build national clinical and translational research
capability.
Goal 2. Provide training and improving the career
development of clinical and translational scientists.
Goal 3. Enhance consortium-wide collaborations.
Goal 4. Improve the health of our communities and the
nation.
Goal 5. Advance T1 translational research.
Various M.D./M.B. Ph.D. programmes and master pro-
grammes focussing on TR are now also available and further
training supported by dedicated fellowships are providing a
clearer career pathway for both clinician-scientists and basic
scientists.
Despite these encouraging schemes to entice and train
young researchers in translational projects, there are still a
number of challenges that need to be addressed if we are
to ensure that the brightest minds will continue to enter
this field of investigation. In clinical medicine, there are still
some myths and misconceptions about the role of research
in training programmes such as:
(i) research has no place in a clinician’s training pro-
gramme;
(ii) there is no place for basic research in the clinical
training programme;
(iii) every surgical trainee should do some basic research;
(iv) clinicians should only engage in clinical research.
These need to be tackled at faculty, institutional, and
national levels.
Another challenge is that of career progression and
promotion, and obtaining a tenured post in academic
medicine or in a university science department. Current
criteria for promotion still rely heavily on individual research
output such as high impact publications, grants, and invited
lectures. Investigators involved in TR may not be able to
produce the required evidence of their contribution such as
an adequate publication record, since translational projects
generally take longer to complete. They are also likely to
be part of a fairly large interdisciplinary team and their
role in publications and on grants may not be apparent.
Indeed the latter may be diﬃcult to assess since they may
be working outside their recognised disciplines. To improve
this situation, institutions need to ensure that their tenure
and promotions systems are able to evaluate and recognise
the contributions investigators conducting TR make. Many
institutions are working towards this, for example, by using
reviewers with diverse expertise and understanding of TR
and moving away from “traditional” assessment criteria.
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The lack of role models and mentors in this area has
been identified as a significant barrier by researchers trying
to engage in TR. Mentorship is increasingly recognised as
invaluable in the development of early career researchers
into independent investigators and most institutions have
in place mentoring programmes. In the UK, the Academy
of Medical Sciences has an eﬀective national mentoring
and outreach scheme supported by the Department of
Health and the NIHR which has been in place since 2002.
This scheme specifically oﬀers one-to-one mentoring for
early career clinician-scientists by Academy Fellows who are
leading scientists in their fields [9]. Further, the importance
of training of eﬀective mentors is also now recognised [10].
5. Continuing Problems
Despite increased eﬀorts over the past decade, the eﬀective-
ness of these initiatives is still unclear. Outcomes of TR,
particularly in the short term, have been diﬃcult to measure,
mainly due to the long timelines between discovery and clini-
cal implementation. Traditional measures of research output
such as contribution to high-impact publicationsmay also be
diﬃcult to assess since TR publications usually involve mul-
tiple, interdisciplinary authors with varying roles and contri-
butions. From the investigators’ perspective, whilst there are
examples of successful partnerships [11], recent discussions
and publications continue to cite similar issues as barriers to
TR across diﬀerent specialties, both by basic scientists and by
clinician-scientists. For example, in 2009, the NIH Task Force
on Research in Emergency Medicine held a series of round-
table discussions on emergency care research, with the aims
of identifying key research questions in emergency care and
barriers to research in emergency care [12–15]. The main
barriers identified across the areas of emergency care were
shortage of trained investigators, lack of role models and
training opportunities, inadequate protected research time,
poorly defined research-based career paths, the culture of
valuing clinical care over research, poor infrastructure, lack
of interdisciplinary research collaborations, lack of relevant
funding streams, and ethical and regulatory issues. Of the
recommendations made to address these issues, it was felt
that formation and development of emergency care clinical
research networks will be particularly beneficial to provide
shared infrastructure and project support, as well as to
increase patient accruals and trial size and improve eﬃciency
[15]. The Federation of American Societies for Experimental
Biology (FASEB) held a symposium entitled Engaging Basic
Scientists in Translational Research: Identifying Opportunities,
Overcoming Obstacles in March 2011 to identify and address
issues important to basic scientists conducting TR [16].
The main challenges identified again included diﬀerences
in culture and mindset between basic and clinical scien-
tists, insuﬃcient or nonsupportive infrastructure (including
regulatory issues), diﬃculties developing and sustaining
collaborations, inadequate training, insuﬃcient funding, and
lack of incentives and rewards. Recommendations weremade
as to how to tackle these hurdles, emphasizing the roles
of institutions, professional societies, funding organisations,
and individual scientists [17].
As discoveries move from “bench to bedside”, invaluable
information may be gained by moving back from the
“bedside to the bench”, for example, to understand important
underlying mechanisms and unexpected findings and to
make improvements. Similar barriers work against this arm
of TR, such as poor communication of clinical challenges to
basic scientists and lack of funding beyond the clinical trial.
Unless researchers, be they clinical or scientific, can see “the
light at the end of the (TR) tunnel,” we are likely to lose
out on capturing, and captivating, high calibre translational
researchers. Some of the TR initiatives are still in their early
phases, so it is likely that further improvements will be seen
in the near future.
6. Current Funding and Critical Issues: How Far
Have We Come?
To overcome these barriers, increased sustained funding
dedicated to TR is clearly essential to enable innovative
approaches towards research to be developed. These include
the building of research units that incorporate multidisci-
plinary groups which may involve bioinformaticians, statis-
ticians, engineers, basic scientists, and clinicians; increas-
ing expert support in regulatory issues and clinical trial
design and conduct; as well as the initiation of forums for
interdisciplinary discussion. The latter encourages discussion
and networking between basic scientists and clinicians,
initiation of interdisciplinary collaborations and the building
of appropriate research teams.
In the USA and the UK, significant resources have already
been directed towards TR via key initiatives. In the USA,
the National Institutes of Health (NIH) launched the NIH
Roadmap in 2003 aimed at supporting TR [18], followed
by the Clinical and Translational Science Awards (CTSA)
scheme in 2006 [8]. The CTSA scheme aimed to develop
a consortium of institutes that would transform clinical
and translational research; 60 academic medical centres
are now funded, receiving USA$500 million annually. In
the UK, the National Institute of Health Research (NIHR)
spent £45 million to fund the first Biomedical Research
Centres (BRC) and Biomedical Research Units (BRU) in
2007 and 2008 within NHS and university partnerships to
drive translational research. A second round was launched in
2011, spending £775 million on 11 BRCs and 20 BRUs. BRCs
support TR across a wide range of disease areas while BRUs
are smaller groups working in priority areas including car-
diovascular disease, dementia, hearing problems, nutrition
and lifestyle, gastrointestinal, musculoskeletal, and respira-
tory disease [19]. Similarly, the MRC in a further expansion
plan at the end of 2011 announced its commitment to a
new £354m investment over the next 4 years. Specific calls
were broadened to include stratified medicine research. This
aims at understanding why groups of patients with the same
diagnosis often diﬀer in response to the same treatment
and sets out to develop UK-wide research consortia each
focussed on specific disease areas. The goal is to stratify
disease processes and develop a clearer understanding of the
underlying mechanisms that will eventually lead to future
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tailoring of treatment to individual patients and improve cost
eﬀectiveness. Additionally, the associated “Challenge Grants”
will support ambitious, challenge-led studies of disease
mechanisms in humans. These studies will produce major
new mechanistic insights into human disease, with potential
applicability to new therapeutic approaches and opportuni-
ties for “reverse translation” to more basic research. Other
major funding bodies, including the Wellcome Trust, the
Medical Research Council, the British Heart Foundation,
and Heart Research UK, have also focussed support on TR.
For example, Heart Research UK funded almost £500K in
2010 on four projects under its Translational Research Grants
programme [20] whilst theWellcome Trust spent £59million
on TR in 2010 [21].
Nevertheless, with the growing realisation that the
research infrastructure needed to cope with the broad spec-
trum of diﬀerent diseases and treatment requirements can-
not be comprehensively covered by any individual country
alone, the beginning of 2012 also saw major commitments to
TR widening and expanding with the initiation and launch
of a new European research infrastructure initiative, the
European Advanced Translational Research InfraStructure in
Medicine (EATRIS).
Within this pan-European network of eleven major insti-
tutes across Europe, several governments and research bodies
aim to ensure that the best research facilities for TR will
be shared by the whole research community. Central broad
areas for study include imaging and tracer development,
biomarkers, vaccines, advanced therapy medicinal products,
and infectious diseases.
In London, the new £73 million Imperial Centre for
Translational and Experimental Medicine (ICTEM) will play
a major role in the programme by combining laboratory
space for 450 scientists including chemists, biologists, and
engineers with dedicated facilities for assessing and devel-
oping novel medical therapies through clinical trials. Initial
priority areas will include cancer, infection, cardiovascular,
metabolic, and neurological diseases. The overall concept
of the EATRIS programme is to bring together the best
biomedical and clinical scientists and allow them access to
state-of-the-art research facilities, techniques, and expertise
covering the entire developmental chain from validation,
compound libraries, good manufacturing practice, and so
forth to research hospitals. Education is also a key element of
the programme that will train scientists as well as technicians
and nurses to think outside their immediate disciplines and
provide information about clinical needs and regulatory
requirements.
In the light of these initiatives, industry has also taken up
the challenge of TR and funded projects independently, or in
partnership with various funding bodies or with major aca-
demic health centres. A fine example of an industry-medical
charity partnership is the MSD Wellcome Trust Hilleman
Laboratories which were established in India in 2009, as a
£90 million joint venture between MSD Laboratories India
LLC (a wholly owned subsidiary of Merck & Co. Inc. USA)
and the Wellcome Trust. The aim of this collaboration is to
develop high-impact aﬀordable vaccines for people in devel-
oping countries. Other companies have since followed suit.
The MRC is investing £10M in unique open innovation col-
laboration with AstraZeneca which has also formed partner-
ships with the Karolinska Institute to screen tissue banks for
novel proteomic biomarkers that may signal underlying dis-
ease or susceptibility to risk. Similarly, Gentris Corporation
has linked with academia in China to develop and validate
new genomic markers while Aﬀymetrix and Leica Microsys-
tems are developing complementary companion diagnostic
tests for personalized medicine by significantly increasing
high through-put, in situ hybridization analyses. These part-
nerships provide academic researchers with unprecedented
access to high-quality clinical and pre-clinical compounds,
the building blocks of new drugs, in order to help better
understand a spectrum of diseases with a view to exploring
new treatments. Such collaboration have the potential to
be transformational in stimulating relationships between
academia and industry. The findings of the research will help
deliver growth to the pharmaceutical and biotech industry.
7. Articles in the Current Issue
Despite concerns, there does seem to be a burgeoning of pub-
lications pertaining to TR. Thus, it is heartening to read in
this special issue of Cardiology Research and Practice articles
devoted to translational science and research. These papers
address a range of cardiovascular diseases including periph-
eral arterial disease, abdominal aortic aneurysms, systemic
sclerosis, and pulmonary artery hypertension, discussing
recent findings on disease initiation and development as well
as novel therapies that are currently being explored. They
illustrate how improved knowledge of basic pathological
processes and their regulatory mechanisms are contributing
to our understanding of specific diseases. For example, Spirig
et al. [22] and Patel et al. [23] discuss the increasingly
recognised link between innate immune signalling and
cardiovascular diseases whilst Williams et al. [24] and
Dooley et al. [25] demonstrate the potential of modulating
the ubiquitous nitric oxide pathway in the treatment of
peripheral arterial disease and systemic sclerosis, respectively.
The impact of advanced technologies on TR is clearly seen in
the field of genetics and in this issue, Harrison and colleagues
describe the use of genomics to study pathways involved in
abdominal aortic aneurysm development [26] whist Capo-
rali & Emanueli discuss the role of microRNAs in vascular
repair [27]. In terms of novel therapies, contributions on
remote ischaemia preconditioning [28], stem cell therapies
[29], and tissue protective strategies [30] illustrate their
potential in the cardiovascular field. This certainly indicates
that TR is being pursued intensively by these investigators
and departments, and in subjects that address areas of
either unmet, or indeed, unrealized, clinical need. It is also
encouraging to see that most of the papers in this issue come
from multidisciplinary groups of clinicians and scientists at
various stages of their careers working in close partnership.
Collaborations such are these are the driving forces of TR in
terms of bringing together expertise, integrating basic science
and clinical applications, and training future generations of
clinician-scientists.
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8. Concluding Remarks
TR is not for the faint hearted. The constant challenges of
teaching, researching, publishing, and competing for limited
sources of funding, coupled with pursuing career aims and
ambitions, can seem daunting. However, it can also be a
deeply satisfying and exhilarating endeavour, especially when
the fruits of the experimental laboratory are translated into
improved healthcare delivery to our patients.
Finally, we feel that TR has a central and pivotal role in
harnessing significant discoveries in biomedical science for
the benefit of our patients. To the sceptics who ask: “Where is
the evidence that TRmatters?” we would answer: “As with Sir
Christopher Wren’s monuments, the evidence is all around
us.”
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